Y-mAbs(YMAB) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024 ● Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024 ● Achieved extension of primary DANYELZA U.S. patent through February 2034 ● Continued geographic expansion of DANYELZA with new market revenue ...